The GABA system: the brain's natural brake
GABA (gamma-aminobutyric acid) is the brain's primary inhibitory neurotransmitter. When GABA binds to GABA-A receptors, it opens chloride ion channels, allowing negatively charged chloride ions to flow into nerve cells. This reduces the electrical excitability of neurons — essentially acting as a brake on brain activity.
How zopiclone acts on GABA-A receptors
Zopiclone is a positive allosteric modulator of the GABA-A receptor. It binds to the benzodiazepine binding site on the GABA-A receptor complex, increasing the frequency of chloride channel opening in response to GABA. The result:
- Reduced neuronal excitability across the brain
- Sedation and faster sleep onset (typically 30–60 minutes)
- Reduced anxiety and muscle relaxation
- Suppressed cortical arousal
How zopiclone differs from benzodiazepines
Although zopiclone acts on the same GABA-A receptor site, it has a different chemical structure (cyclopyrrolone) and slightly different receptor subunit selectivity compared to benzodiazepines. In theory, this selectivity was hoped to produce fewer side effects. In clinical practice, however, zopiclone carries very similar risks of dependence, tolerance, and withdrawal.
Tolerance and why it develops
With repeated use, the brain compensates by downregulating GABA-A receptors — reducing their number or sensitivity. This means zopiclone becomes progressively less effective. It is one reason the BNF limits treatment to 2–4 weeks.